Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Updates in Corneal and Glaucoma Surgery
share announcement

Updates in Corneal and Glaucoma Surgery

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Ophthalmology".

Deadline for manuscript submissions: closed (30 March 2024) | Viewed by 3736

Special Issue Editors

Dr. Karl Anders Knutsson

E-Mail Website
Guest Editor
Cornea and Ocular Surface Unit, San Raffaele Scientific Institute, Milan, Italy
Interests: ophthalmology surgery; corneal transplantation; lamellar keratoplasty; glaucoma surgery
Dr. Giacinto Triolo

E-Mail Website
Guest Editor
Fatebenefratelli and Ophthalmic Hospital, Piazza Principessa Clotilde, 5–20121 Milan, Italy
Interests: optical coherence tomography; optical coherence tomography angiography; glaucoma; neurodegeneration; optic nerve; retina; retinal ganglion cells; retinal nerve fibers; glaucoma surgery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Corneal and glaucoma surgery have continued their rapid development in recent years. Corneal transplantation has been revolutionized by anterior and posterior lamellar techniques, whereas corneal collagen cross-linking has completely changed the management of keratoconus and other forms of corneal ectasia. The development of new devices for micro-invasive glaucoma surgery (MIGS) has brought new therapeutic prospects to glaucoma patients, together with newly designed tube implants. This Special Issue intends to provide an update of the current and future surgical techniques in the subspecialty fields of corneal and glaucoma surgery.

Dr. Karl Anders Knutsson
Dr. Giacinto Triolo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • corneal transplantation
  • lamellar keratoplasty
  • deep anterior lamellar keratoplasty
  • endothelial keratoplasty
  • micro invasive glaucoma surgery
  • glaucoma tube shunts
  • glaucoma surgery

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

10 pages, 1475 KiB  
Article
Reassessing Trabeculectomy: A Long-Term Study with Stringent Success Criteria
by Philip Braun, Daniel Böhringer, Jens Jordan, Michael Reich, Philip Keye, Thomas Reinhard and Jan Lübke
J. Clin. Med. 2024, 13(6), 1629; https://doi.org/10.3390/jcm13061629 - 12 Mar 2024
Viewed by 448
Abstract
Background: The aim was to evaluate the long-term outcome and efficacy of primary trabeculectomy with adjunctive mitomycin c (MMC) for treating glaucoma. Methods: We examined the medical records of 286 eyes that underwent trabeculectomy between 2008 and 2009 at the University Eye Hospital [...] Read more.
Background: The aim was to evaluate the long-term outcome and efficacy of primary trabeculectomy with adjunctive mitomycin c (MMC) for treating glaucoma. Methods: We examined the medical records of 286 eyes that underwent trabeculectomy between 2008 and 2009 at the University Eye Hospital in Freiburg, Germany. Preoperative and follow-up data were collected, including intraocular pressure (IOP) measurements, surgical glaucoma interventions, and prescribed glaucoma medication. The first success criterion was defined as IOP ≤ 15 mmHg with no use of pressure-lowering medication by the patient, the second criterion was defined as the absence of surgical revision, and the third criterion as no further IOP-lowering surgery excluding early revisions following trabeculectomy. Statistical analyses comprised Cox regression and Kaplan–Meier survival estimations. Results: The mean follow-up duration was 1841 days (5 years). The mean preoperative IOP was 26.1 mmHg. Evaluating the success criteria at the time of average follow-up yielded a success rate of only 25% for the first criterion but 80% for both the second and third success criteria. Conclusions: The findings suggest that trabeculectomy with adjunctive MMC can be an effective procedure for permanently lowering IOP. However, surgical revisions and/or further glaucoma surgeries might still be needed. The long-term success rate is lower in comparison to previous research, which may be explained by the stricter success criteria in our study. Full article
(This article belongs to the Special Issue Updates in Corneal and Glaucoma Surgery)
►▼ Show Figures

Figure 1

14 pages, 2754 KiB  
Article
Safety and Efficacy of Three Modifications of Canaloplasty to Treat Open-Angle Glaucoma: 3-Year Outcomes
by Aleksandra K. Kicińska and Marek Rękas
J. Clin. Med. 2023, 12(20), 6475; https://doi.org/10.3390/jcm12206475 - 11 Oct 2023
Viewed by 626
Abstract
Background: This is a report of 3-year results of a prospective assessment of three modifications of canaloplasty (C): ab externo (ABeC), mini-canaloplasty (miniABeC), and ab interno (ABiC) performed concomitantly with cataract removal in subjects suffering from primary open-angle glaucoma (POAG). Methods: Forty-eight individuals [...] Read more.
Background: This is a report of 3-year results of a prospective assessment of three modifications of canaloplasty (C): ab externo (ABeC), mini-canaloplasty (miniABeC), and ab interno (ABiC) performed concomitantly with cataract removal in subjects suffering from primary open-angle glaucoma (POAG). Methods: Forty-eight individuals were randomized for one of the surgeries: ABeC, miniABeC, or ABiC and cataract removal—16 eyes for each group. Follow-up examinations were carried out on the day of the surgery, on days 1 and 7, after 1, 3, 6 months, and at 1, 2, and 3 years. Complete and qualified success was an IOP ≤ 15 mmHg without or with antiglaucoma eye drops, respectively. The IOP reduction of 20% or more was considered an additional success criterion. Results: Within three years the probability of qualified success was ABiC and miniABeC—94%, ABeC—100%, and of complete success ABiC—75%, miniABeC—100%. At the 3-year follow-up, the median IOP decreased from 22 to 15 mmHg in the ABeC group (p = 0.001), from 22 to 15 mmHg in the miniABeC group 15 (p < 0.001), and from 21 to 15 mmHg in the ABiC group (p = 0.001) compared to the post-washout stage. The IOP dropped by 20% or more without medications in 56.2% of patients post ABiC, 68.8% post miniABeC and 75% post ABeC. The median number of antiglaucoma medications dropped in all three groups; at the 3-year follow-up, only one patient following ABeC and four subjects following miniABeC required treatment. One patient required reoperation and further intensification of topical treatment—post miniABeC. The levels of IOP, CDVA, and success probability at the 36-month follow-up showed no significant difference for individual groups. Conclusions: ABeC, miniABeC, and ABiC have significant IOP-lowering potential in individuals diagnosed with POAG at a mild to moderate stage and no history of IOP ≥ 30 mmHg with a good safety profile. Full article
(This article belongs to the Special Issue Updates in Corneal and Glaucoma Surgery)
►▼ Show Figures

Figure 1

Other

Jump to: Research

8 pages, 1314 KiB  
Brief Report
Effects of Postoperative Atropine Eye Drops on Visual Quality in Patients Undergoing Trabeculectomy
by Panagiotis Laspas, Elisa Maier, Alexander Schuster, Colm McAlinden, Norbert Pfeiffer and Esther Hoffmann
J. Clin. Med. 2023, 12(3), 763; https://doi.org/10.3390/jcm12030763 - 18 Jan 2023
Viewed by 2283
Abstract
The aim of this study was to investigate the effects of atropine on patients’ perception of visual quality after trabeculectomy. Forty patients undergoing standard trabeculectomy with mitomycin C were enrolled in this prospective randomized study. All surgeries were conducted at the ophthalmology department [...] Read more.
The aim of this study was to investigate the effects of atropine on patients’ perception of visual quality after trabeculectomy. Forty patients undergoing standard trabeculectomy with mitomycin C were enrolled in this prospective randomized study. All surgeries were conducted at the ophthalmology department of the University Medical Center of Mainz, Germany. All patients received the same postoperative treatment with ofloxacin and dexamethasone eye drops. Following randomization of patients into two groups of 20 patients, the intervention group also received atropine eye drops three times daily for the first 2 days after surgery to stabilize the anterior chamber. All patients completed a visual quality questionnaire before surgery and 2 and 6 weeks after surgery. Results were compared using the Wilcoxon test. After surgery, there was a reduction in visual quality in all patients. Patients who received atropine eye drops described a greater and longer-lasting reduction in visual quality than those who did not receive atropine eye drops. Trabeculectomy often leads to a transient reduction in visual quality. This reduction was greater in severity and duration in patients who received postoperative atropine eye drops. Thus, unless there is an underlying medical necessity, we would discourage the application of atropine as a standard therapy for trabeculectomy surgery. Full article
(This article belongs to the Special Issue Updates in Corneal and Glaucoma Surgery)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop